Exact Sciences Launches the Oncodetect ™ Molecular Residual Disease Test
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced the launch of Oncodetect™—a new test designed to detect molecular residual disease (MRD) across multiple solid tumors. The Oncodetect test provides patients and their healthcare providers with the insights needed to make more informed decisions throughout the treatment process, advancing the field of MRD testing.
The Oncodetect test delivers clear "Detected' or 'Not Detected' results, accompanied by quantitative data to help support adjuvant therapy decisions, evaluate treatment response, and monitor cancer recurrence. Notably, patients who test positive for ctDNA with the Oncodetect test during surveillance are 50 times more likely to experience cancer recurrence than those with negative results 1. Highly sensitive and personalized, the test tracks up to 200 tumor-specific variants and identifies even trace amounts of ctDNA—down to 1 ctDNA molecule in 20,000 cfDNA ‡ molecules. This sensitivity enables earlier detection of CRC recurrence compared to imaging alone 1,2.
"Exact Sciences is transforming cancer care by delivering tests that provide the clarity patients and physicians need to make confident decisions," said Brian Baranick, Executive Vice President and General Manager, Precision Oncology at Exact Sciences. "After surgery and definitive therapy, such as chemotherapy or radiation, the risk for cancer recurrence remains a major concern. Advanced detection tools like the Oncodetect test help bridge that gap by providing clinical insights at critical periods, leading to more informed treatment decisions and personalized care.'
Backed by robust clinical validation, including data from the Alpha-CORRECT study—one of the longest-followed MRD cohorts for CRC recurrence with nearly five years of follow-up—the Oncodetect test enhances understanding of cancer recurrence and helps support timely, personalized treatment decisions. Exact Sciences is actively working with Medicare to secure reimbursement for the test, ensuring broad patient access nationwide. The company is also advancing clinical and analytical validation studies across multiple solid tumors, supported by strategic partnerships for multi-cancer evidence generation.
'Exact Sciences is a longtime trusted partner in addressing the critical unmet needs in colorectal cancer care, ensuring patients have the insights they need to navigate treatment with confidence,' said Vanessa Ghigliotty, Certified Patient Navigator & Chair, Patient Advisory Board, GI Cancers Alliance §. 'For those facing the uncertainty of recurrence, tumor-informed MRD tests like the Oncodetect test can provide clear, timely answers—empowering patients to take an active role in their care and receive the right treatment at the right time for better outcomes.'
The Oncodetect test builds on 20 years of genomic testing excellence established by the Oncotype DX Breast Recurrence Score ® test. Integrated into a world-class digital experience, supported by the ExactNexus™ technology platform, the Oncodetect test can be ordered with other Exact Sciences tests, including OncoExTra ® (comprehensive genomic profiling) and Riskguard® (hereditary cancer testing). With more than 3 million American patients 3 eligible for MRD testing, Exact Sciences is well-positioned to shape the future of personalized care.
The Oncodetect test is now available. For more information, visit www.oncodetect.com
* Circulating tumor DNA
† The Oncodetect test was clinically validated in colorectal cancer patients with stage II-IV disease. Performance characteristics may not apply in tumor types not included in this test's clinical validation.
‡ Cell-free DNA
§ Ghigliotty attended the March 2025 Cologuard Classic through a grant from Exact Sciences to the GI Cancers Alliance, which has also received prior funding from the company.
References
Diergaarde B, Young G, Hall DW, Mazloom A, Costa G, Subramaniam S, Palomares M, Garces J, Baehner FL, Schoen RE; and other members of the Exact Sciences MRD Group. Circulating tumor DNA as a marker of recurrence risk in Stage III colorectal cancer: The α‐CORRECT study. Journal of Surgical Oncology.
Santonja et al 2023 EMBO (https://www.embopress.org/doi/full/10.15252/emmm.202216505)
Data source on file
Internal product profile of the Oncodetect test
About the Oncodetect test
Developed by Exact Sciences, the Oncodetect test is a tumor-informed molecular residual disease (MRD) test designed to provide a personalized approach to detecting and monitoring residual cancer in patients with solid tumors. By leveraging the company's expertise in whole exome sequencing, the Oncodetect test analyzes circulating tumor DNA (ctDNA) shed into the bloodstream by tumors, offering critical insights into changes in ctDNA levels over time. This quantitative assessment of ctDNA (measured as MTM/mL) helps healthcare providers better understand a patient's MRD status and make informed treatment decisions 4.
About Exact Sciences Corp.
A leading provider of cancer screening and diagnostic tests, Exact Sciences gives patients and health care professionals the clarity needed to take life-changing action earlier. Building on the success of the Cologuard® and Oncotype® tests, Exact Sciences is investing in its pipeline to develop innovative solutions for use before, during, and after a cancer diagnosis. For more information, visit ExactSciences.com, follow Exact Sciences on X (formerly known as Twitter) @ExactSciences, or find Exact Sciences on LinkedIn and Facebook.
Oncodetect, Oncotype, Oncotype DX Breast Recurrence Score, and OncoExTra are trademarks of Genomic Health, Inc., a wholly owned subsidiary of Exact Sciences. Exact Sciences, Cologuard, and Riskguard are trademarks of Exact Sciences Corporation. Oncodetect, Cologuard, Riskguard, and OncoExTra are only available in the United States.
Forward-Looking Statement
This news release contains forward-looking statements concerning our expectations, anticipations, intentions, beliefs, or strategies regarding the future. These forward-looking statements are based on assumptions that we have made as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions and events to differ materially from those anticipated. Therefore, you should not place undue reliance on forward-looking statements. Examples of forward-looking statements include, among others, statements regarding our expectations for the commercialization of the Oncodetect test and the performance of the Oncodetect test in a commercial setting. Risks and uncertainties that may affect our forward-looking statements are described in the Risk Factors sections of our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q, and in our other reports filed with the Securities and Exchange Commission. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
11 hours ago
- Yahoo
Rocket Lab Stock Is Soaring Again: Should You Buy It Under $30?
Rocket Lab is gaining a reputation for reliability in the rocket launch and space systems market. The company is building on its capabilities and improving its relationships as a defense contractor. While this young sector shows a lot of great promise, the stock looks overvalued today. 10 stocks we like better than Rocket Lab › Space is the final frontier, and it is now turning into a burgeoning economy. Researchers estimate that the space economy is worth over $500 billion with heavy spending from governments around the world along with private-company partners, and that figure is expected to grow to around $1.8 trillion a year by 2035. This is a huge opportunity for start-ups, perhaps rivaled only by artificial intelligence (AI) over the next decade when it comes to both growth rates and size. One company that dominates (and actually built) the entire space market is SpaceX. It's privately held, but luckily, investors have other space economy stocks that are turning into promising businesses. Enter Rocket Lab (NASDAQ: RKLB), the space flight company increasingly competing with SpaceX and developing promising capabilities to grow its presence in this large market. The stock has begun to soar again and is trading at around $26 as of this writing. Should you buy while shares are still under $30? Rocket Lab began its journey in the space economy with its small Electron rocket. It has now begun to expand and vertically integrate various space economy segments. It just acquired a company called Geost for $275 million. Geost develops optical and infrared capabilities for satellites with a focus on selling to the U.S. government's national security satellites. Rocket Lab is used by the government to launch its payloads into space. Now, it will be helping to build and operate these payloads for customers. It keeps vertically integrating its launch and space systems, which gives it a competitive advantage over other companies that only offer one or the other (SpaceX is the only other vertically integrated player). Rocket Lab offers solar energy, radio systems, and software for companies sending missions operating in space. This is why its backlog was over $1 billion as of the end of last quarter. Electron launch missions will continue throughout 2025, hopefully building on the company's strong safety and reliability record. The next step for the company will be testing and launching its larger Neutron rocket for customers. Testing is underway for this rocket right now with a planned mission for a confidential customer sometime in 2026. Larger rockets mean larger payloads, which means more revenue per launch. It also will give the company more of an opportunity to sell its space systems on these launches. The Neutron is the key for Rocket Lab to take the next step in its capabilities as a space flight company and to grow its backlog and revenue. Defense contracts have been a huge part of Rocket Lab's business. It currently helps with Air Force missions and a hypersonic testing program called HASTE. It was recently added to the National Security Space Launch (NSSL) program for its Neutron rocket, another reason why this new rocket is so important for the company's future. A growing relationship with the U.S. government could not have come at a better time for Rocket Lab. The government is set on spending a ton of money on space solutions as the next frontier in national defense. For example, the proposed Golden Dome missile defense project for the U.S. would cost an estimated $175 billion over three years to build. The company would be a prime candidate to win subcontracts for this ambitious project. As the Neutron comes on line and Rocket Lab builds up its capabilities and reputation in the space economy, we should see its backlog climb higher. This is a key indicator for investors to watch. The current backlog will have around half of its revenue recognized over the next 12 months, and half in later periods. In order to grow revenue over the long term, the company will need to grow its backlog and win more contracts from government and commercial customers. There is a lot of potential with Rocket Lab's business, but it might all be priced into the stock (and more) right now. It has a market cap of $12.3 billion. Revenue was only $466 million over the last 12 months. The company has never generated a profit and continues to lose money. If the company is successful with its ambitions to build a vertically integrated space company, it will eventually generate billions of dollars in revenue -- perhaps tens of billions 15 to 20 years from now. However, that is a long way off, and the stock looks fully priced versus what the company can accomplish in the next few years. For this reason, the stock looks like one to avoid even with the price under $30. The business may be promising, but the market is getting ahead of itself with Rocket Lab at the moment. This is a high-risk stock to keep out of your portfolio right now. Before you buy stock in Rocket Lab, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Rocket Lab wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,538!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $869,841!* Now, it's worth noting Stock Advisor's total average return is 789% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 Brett Schafer has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Rocket Lab USA. The Motley Fool has a disclosure policy. Rocket Lab Stock Is Soaring Again: Should You Buy It Under $30? was originally published by The Motley Fool
Yahoo
16 hours ago
- Yahoo
Semler Scientific, Inc. (SMLR) Faces Scrutiny from Edelson Lechtzin LLP
On June 4, 2025, Edelson Lechtzin LLP announced that it has initiated an inquiry into whether the healthcare technology company, Semler Scientific, Inc. (NASDAQ:SMLR), misled investors about its business operations regarding claims tied to its QuantaFlo diagnostic device. A doctor in focus surrounded by colleagues in a hospital setting. In an annual report filed by Semler Scientific, Inc. (NASDAQ:SMLR) on February 28, 2025, the company disclosed that the U.S. Department of Justice (DOJ) was evaluating a potential False Claims Act case. The report triggered immediate market reaction, with the company's shares plummeting by 9.4% to close at $38.89 on March 3. Initiating the inquiry, Edelson Lechtzin LLP has asked for the public and stakeholders' help. Edelson urges those with non-public information regarding Semler Scientific, Inc. (NASDAQ:SMLR) to come forward and assist them in the investigation. It also encourages the company's investors who have suffered losses to follow the inquiry to learn more. The investor confidence has been significantly fluctuating since the disclosure. The stock's performance, which gained 6.49% last month, declined by 13.46% last week. The California-based company, Semler Scientific, Inc. (NASDAQ:SMLR), is known for developing non-invasive medical tools, with QuantaFlo being its most prominent product. Focusing on early disease detection and chronic condition management, the company has positioned itself between healthcare and technology. While we acknowledge the potential of SMLR as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 10 Unstoppable Dividend Stocks to Buy Now and 11 Oversold Global Stocks to Buy According to Hedge Funds Disclosure: None. Sign in to access your portfolio
Yahoo
21 hours ago
- Yahoo
H.C. Wainwright Initiates Coverage of Akebia Therapeutics (AKBA) With Buy Rating
Matthew Caufield, an analyst from H.C. Wainwright, initiated coverage of Akebia Therapeutics, Inc. (NASDAQ:AKBA) with a Buy rating and a $8 price target, on June 4. The analyst gave the optimistic rating due to the company's VAFSEO product and its potential in the CKD anemia market. VAFSEO is an approved treatment for anemia in adults with chronic kidney disease on dialysis. According to the analyst, the treatment is gaining considerable momentum among dialysis organizations, and this trend is anticipated to support near-term growth. He expects VAFSEO's ongoing launch to offset the effect of generics on AURYXIA, another product by Akebia Therapeutics, Inc. (NASDAQ:AKBA) that deals with hyperphosphatemia. A biopharmaceutical team in a laboratory analyzing new compounds to develop therapeutics. The analyst also reasoned that Akebia Therapeutics, Inc. (NASDAQ:AKBA) is positioned for success as it has secured contracts that cover almost all dialysis patients in the US. VAFSEO offers flexibility in its dosing regimen, ranging from 150mg to 600mg, making it a factor that allows for personalized treatment and potentially growing prescriptions. Caufield pointed out VAFSEO's oral administration as another reason supporting the optimistic rating, giving it an advantage over existing therapies, such as iron supplementation and erythropoiesis-stimulating agents. Akebia Therapeutics, Inc. (NASDAQ:AKBA) is a biopharmaceutical company that develops and commercializes drugs to treat metabolic and renal diseases. While we acknowledge the potential of AKBA as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. Sign in to access your portfolio
